Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST)

Peer Review reports

Original Submission
14 Feb 2011	Submitted	Original manuscript
21 Feb 2011	Reviewed	Reviewer Report - Andrew Vickers
16 Mar 2011	Author responded	Author comments - Shiro Tanaka
Resubmission - Version 2
16 Mar 2011	Submitted	Manuscript version 2
16 Mar 2011	Reviewed	Reviewer Report - Andrew Vickers
18 Mar 2011	Author responded	Author comments - Shiro Tanaka
Resubmission - Version 3
18 Mar 2011	Submitted	Manuscript version 3
Publishing
12 May 2011	Editorially accepted
12 May 2011	Article published	10.1186/1745-6215-12-120

Back to article page